|
Immunotherapy
Djukanovic and coworkers investigated the effects of anti-IgE (omalizumab) on airway inflammation in atopic asthma in a placebo-controlled, double-blind, parallel group study. Sixteen weeks of treatment with greater than 0.016 mg/kg omalizumab by subcutaneous injection every 4 weeks was associated with a significant reduction in induced sputum and bronchial mucosal eosinophils, biopsy CD3+, CD4+, and CD8+ cells, and cells staining positively for IL-4. Interestingly, there was no effect of omalizumab treatment on FEV1 or airway hyperresponsiveness, emphasizing once again that these cardinal features of asthma can be disassociated.
1 Citation displayed.
Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
- Ratko Djukanovic, Susan J. Wilson, Monica Kraft, Nizar N. Jarjour, Mark Steel, K. Fan Chung, Weibin Bao, Angel Fowler-Taylor, John Matthews, William W. Busse, Stephen T. Holgate, and John V. Fahy
Am. J. Respir. Crit. Care Med. 170: 583 -593. First published online as doi:10.1164/rccm.200312-1651OC
[Abstract]
[Full text]
|
|
